I don't dispute anything in your post, in fact I basically agree. The issue is that you could have said almost the same thing for the last 2 years. Nuvaring generic was supposed to launch in 2019. It's not even approved yet. Nextstellis should be a game changer but confidence in management's ability to make it all happen has been shot to pieces because of their historical performance. We're all hoping that this time is different but long term holders have been burnt too many times by this management team to count on anything until it actually happens.
MYX Price at posting:
32.8¢ Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)